{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:37:29Z","timestamp":1787503049434,"version":"build-2736575974"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin intervent Radiol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>90Yttrium (Y90) radioembolization has been shown to improve outcomes for primary and metastatic liver cancers, but there is limited understanding of the optimal timing and safety of combining systemic therapies with Y90 treatment. Both therapeutic effects and toxicities could be synergistic depending on the timing and dosing of different coadministration paradigms. In particular, patients with liver-only or liver-dominant metastatic disease progression are often on systemic therapy when referred to interventional radiology for consideration of Y90 treatment. Interventional radiologists are frequently asked to offer insight into whether or not to hold systemic therapy, and for how long, prior to and following transarterial therapy. This study reviews the current evidence regarding the timing and safety of systemic therapy with Y90 treatment for hepatocellular carcinoma, metastatic colorectal carcinoma, intrahepatic cholangiocarcinoma, metastatic neuroendocrine tumors, and other hepatic metastases. A particular focus is placed on the timing, dosing, and toxicities of combined therapy.<\/jats:p>","DOI":"10.1055\/s-0041-1735572","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T18:48:54Z","timestamp":1633632534000},"page":"472-478","source":"Crossref","is-referenced-by-count":6,"title":["Radioembolization in the Setting of Systemic Therapies"],"prefix":"10.1055","volume":"38","author":[{"given":"Tarub S.","family":"Mabud","sequence":"additional","affiliation":[{"name":"Division of Vascular Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Hickey","sequence":"additional","affiliation":[{"name":"Division of Vascular Interventional Radiology, Department of Radiology, NYU Langone Health, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"J M Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.jvir.2015.06.032","article-title":"Gemcitabine and oxaliplatin, but not sorafenib or paclitaxel, have a synergistic effect with yttrium-90 in reducing hepatocellular carcinoma and cholangiocarcinoma cell line viability","volume":"26","author":"J Edeline","year":"2015","journal-title":"J Vasc Interv Radiol"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1634\/theoncologist.12-4-465","article-title":"Design of clinical trials of radiation combined with antiangiogenic therapy","volume":"12","author":"S Senan","year":"2007","journal-title":"Oncologist"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhep.2014.03.023","article-title":"Prospective randomized pilot study of Y90+\/-sorafenib as bridge to transplantation in hepatocellular carcinoma","volume":"61","author":"L Kulik","year":"2014","journal-title":"J Hepatol"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"J Ricke","year":"2019","journal-title":"J Hepatol"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.3747\/co.23.2827","article-title":"Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma","volume":"23","author":"A Salman","year":"2016","journal-title":"Curr Oncol"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"E897","DOI":"10.3390\/cancers12040897","article-title":"Comparison between Y90 radioembolization plus sorafenib and Y90 radioembolization alone in the treatment of hepatocellular carcinoma: a propensity score analysis","volume":"12","author":"A Facciorusso","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"Lancet"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"G K Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"J Bruix","year":"2017","journal-title":"Lancet"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"V Chew","year":"2019","journal-title":"Gut"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12885-020-6613-1","article-title":"Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy","volume":"20","author":"L Craciun","year":"2020","journal-title":"BMC Cancer"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"A X Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"A B El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"ref15","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"R S Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JHC.S187121","article-title":"The immune modulation effect of locoregional therapies and its potential synergy with immunotherapy in hepatocellular carcinoma","volume":"7","author":"P Singh","year":"2020","journal-title":"J Hepatocell Carcinoma"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","article-title":"Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma","volume":"31","author":"C Zhan","year":"2020","journal-title":"J Vasc Interv Radiol"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-0031-1280652","article-title":"Hepatic artery dissection in a patient on bevacizumab resulting in pseudoaneurysm formation","volume":"28","author":"D B Brown","year":"2011","journal-title":"Semin Intervent Radiol"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.21037\/jgo.2017.09.10","article-title":"Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus","volume":"8","author":"A Kennedy","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1023\/A:1013569329846","article-title":"Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer","volume":"12","author":"B Gray","year":"2001","journal-title":"Ann Oncol"},{"issue":"02","key":"ref21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jso.20141","article-title":"Randomised phase 2 trial of SIR-Spheres plus fluorouracil\/leucovorin chemotherapy versus fluorouracil\/leucovorin chemotherapy alone in advanced colorectal cancer","volume":"88","author":"G Van Hazel","year":"2004","journal-title":"J Surg Oncol"},{"issue":"23","key":"ref22","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","article-title":"Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy","volume":"28","author":"A Hendlisz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"M Miwa","year":"1998","journal-title":"Eur J Cancer"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/bjc.2014.344","article-title":"Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer","volume":"111","author":"S J Cohen","year":"2014","journal-title":"Br J Cancer"},{"issue":"02","key":"ref25","first-page":"473","article-title":"Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization: in regard to Hickey et al","volume":"90","author":"S G Putnam","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"H S Wasan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"25","key":"ref27","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2008.20.8116","article-title":"Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy","volume":"27","author":"G A van Hazel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"ref28","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"R J Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2020.38.4_suppl.110","article-title":"Phase I prospective trial of TAS-102 (trifluride and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases","volume":"38","author":"N Fidelman","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"A Grothey","year":"2013","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3389\/fonc.2019.00624","article-title":"Regorafenib prior to selective internal radiation therapy using 90Y-resin microspheres for refractory metastatic colorectal cancer liver metastases: analysis of safety, dosimetry, and molecular markers","volume":"9","author":"A Kennedy","year":"2019","journal-title":"Front Oncol"},{"issue":"08","key":"ref32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/hpb.12441","article-title":"Intrahepatic cholangiocarcinoma: expert consensus statement","volume":"17","author":"S M Weber","year":"2015","journal-title":"HPB (Oxford)"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"944","DOI":"10.21037\/jgo.2019.05.10","article-title":"Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreatobiliary origin","volume":"10","author":"N Nezami","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"J Edeline","year":"2020","journal-title":"JAMA Oncol"},{"issue":"05","key":"ref35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.semnuclmed.2020.05.004","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors","volume":"50","author":"S Basu","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"M Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2967\/jnumed.112.107482","article-title":"90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy","volume":"53","author":"S Ezziddin","year":"2012","journal-title":"J Nucl Med"},{"issue":"08","key":"ref38","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00259-015-3264-6","article-title":"Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases","volume":"43","author":"C E Barbier","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00270-019-02350-2","article-title":"Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy","volume":"43","author":"A JAT Braat","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"02","key":"ref40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"J R Strosberg","year":"2011","journal-title":"Cancer"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/MPA.0000000000001115","article-title":"Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors","volume":"47","author":"M C Soulen","year":"2018","journal-title":"Pancreas"}],"container-title":["Seminars in Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1735572.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T19:02:44Z","timestamp":1633633364000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1735572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":41,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,10,7]]},"published-print":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1735572","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0739-9529","1098-8963"],"issn-type":[{"value":"0739-9529","type":"print"},{"value":"1098-8963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}